<DOC>
	<DOCNO>NCT00446134</DOCNO>
	<brief_summary>The objective study select optimal dose taribavirin compare efficacy safety 3 taribavirin dose level , 20 , 25 , 30 mg/kg/day , versus ribavirin 800 1400 mg/day base body weight , administer combination peginterferon alfa-2b therapy-naive patient chronic Hepatitis C Virus ( HCV ) genotype 1 infection .</brief_summary>
	<brief_title>Taribavirin Phase 2 Dose Finding Study Treatment Hepatitis C Virus ( HCV )</brief_title>
	<detailed_description>The objective study select optimal dose taribavirin compare efficacy safety 3 taribavirin dose level , 20 , 25 , 30 mg/kg/day , versus ribavirin 800 mg/day 1400 mg/day base subject body weight , drug administer combination peginterferon alfa-2b therapy-naive patient chronic Hepatitis C Virus genotype 1 infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subject Inclusion Criteria To eligible enrollment , patient must meet following criterion : 1 . At least 18 year age 2 . Diagnosed compensate chronic HCV genotype 1 infection treat interferon , peginterferon , ribavirin experimental therapy &gt; 28 day 2a Serum HCV RNA &gt; 2000 copies/mL ( 780 IU/mL ) 2b Liver biopsy perform within 3 year prior screen consistent chronic HCV infection 2c Criteria compensate HCV infection , include normal prothrombin time , serum albumin bilirubin level ( unless due nonhepatitis factor ) history evidence bleed esophageal varix , ascites , hepatic encephalopathy 3 History alanine aminotransferase ( ALT ) elevation either within 6 month prior screen , screen , retest 2 week negative screen test , histologic evidence HCV infection detectable viral load 4 Platelet count ≥90,000/mm3 5 Absolute neutrophil count ≥1200/mm3 6 Hemoglobin ≥12.0 g/dL female ≥13.0 g/dL male 7 Antinuclear antibody ( ANA ) titer ≤1:320 8 Serum creatinine &lt; 1.5 mg/dL 9 HbA1c ≤8.5 % diabetic patient 10 Normal adequately control TSH prescription medication 11 Alpha fetoprotein ( AFP ) &lt; 20 ng/mL hepatocellular carcinoma rule ( ultrasound , CT MRI scan ) within 6 month prior study ( Patients AFP &gt; 20 ng/mL must ongoing hepatocellular carcinoma screen study part patient 's routine medical care ) 12 All clinical laboratory value within normal limit , unless judge clinically significant investigator 13 Sterile infertile ( defined vasectomy , tubal ligation , postmenopausal , hysterectomy ) , willing use approve method doublebarrier contraception ( hormonal plus barrier barrier plus barrier , eg , diaphragm plus condom ) time first dose administration 6 month last dose 14 Capable understanding instruction , adhere study schedule requirement , willing provide informed consent Subject Exclusion Criteria Patients follow screen Day 1 visit eligible enrollment study : 1 . Positive HIV HbsAg serology 2 . Severe psychiatric neuropsychiatric disorder include severe depression , history suicidal ideation suicide attempt ( ) . ( This would include patient history suicidal ideation suicide attempt ( ) occur patient minor many year ago ; event occur influence alcohol drug ; suicidal ideation suicide attempt ( ) connect traumatic event ; patient hospitalize treat ; patient obtain psychiatric clearance treatment ) 3 . History clinical manifestation significant metabolic , hematological , pulmonary , ischemic unstable heart disease , gastrointestinal , neurological , renal , urological , endocrine , ophthalmologic ( include severe retinopathy ) , immune mediate disease 4 . History thalassemia hemoglobinopathy ( even hemoglobin normal ) 5 . Chronic hepatic disease hepatitis C 6 . Organ bone marrow transplant 7 . Chronic ( great 30 day ) use immunosuppressive medication include steroid dose equivalent 10 mg prednisone high , 30 day prior anytime course study 8 . Female patient breastfeed positive pregnancy test time study 9 . Males whose female partner pregnant 10 . Patients malignancy diagnose and/or treat within past 5 year , except localize squamous basal cell cancer treat local excision 11 . Patients participate clinical trial receive investigational drug within 30 day prior screen 12 . History alcoholism drug addiction 1 year prior screen 13 . The use methadone , buprenorphine similar drug , regardless prescribe indication length time patient drug 14 . Chronic ( &gt; 4 week duration ) diarrhea , include irritable bowel disease 15 . Fibrosis score F4 ( cirrhosis ) base Metavir equivalent index 16 . Weight &gt; 128 kg &lt; 40 kg 17 . Patients infect mixed HCV genotype</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Phase 2b Dose-Ranging Study</keyword>
</DOC>